Alpine Woods Capital Investors LLC Purchases 1,255 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Alpine Woods Capital Investors LLC boosted its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 21.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,985 shares of the company’s stock after purchasing an additional 1,255 shares during the period. Alpine Woods Capital Investors LLC’s holdings in CRISPR Therapeutics were worth $275,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Highline Wealth Partners LLC purchased a new position in CRISPR Therapeutics during the 4th quarter valued at $39,000. Western Pacific Wealth Management LP lifted its position in shares of CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of CRISPR Therapeutics during the third quarter valued at $40,000. Darwin Wealth Management LLC purchased a new position in CRISPR Therapeutics in the 3rd quarter worth about $43,000. Finally, Spire Wealth Management boosted its position in CRISPR Therapeutics by 303.7% in the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after buying an additional 1,482 shares during the period. Institutional investors own 69.20% of the company’s stock.

Insider Buying and Selling at CRISPR Therapeutics

In other news, Director John Greene acquired 7,000 shares of the business’s stock in a transaction on Wednesday, February 26th. The stock was bought at an average price of $44.85 per share, with a total value of $313,950.00. Following the completion of the acquisition, the director now owns 7,000 shares of the company’s stock, valued at approximately $313,950. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the transaction, the general counsel now directly owns 77,530 shares of the company’s stock, valued at $3,288,822.60. The trade was a 3.55 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,381 shares of company stock valued at $1,608,243. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Trading Down 3.4 %

NASDAQ CRSP opened at $41.99 on Friday. The stock has a market cap of $3.60 billion, a P/E ratio of -9.61 and a beta of 1.77. The company has a fifty day simple moving average of $43.03 and a two-hundred day simple moving average of $45.63. CRISPR Therapeutics AG has a 12-month low of $36.52 and a 12-month high of $75.91.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, sell-side analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Ratings Changes

CRSP has been the topic of a number of research analyst reports. TD Cowen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price on the stock in a research note on Wednesday, February 12th. Evercore ISI upgraded shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $60.00 to $99.00 in a research note on Friday, February 14th. Stifel Nicolaus dropped their price objective on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research note on Thursday, February 13th. Truist Financial increased their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Finally, Morgan Stanley increased their price objective on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a research note on Friday, February 14th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $73.11.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.